ClinicalTrials.gg
CompletedNCT02283788Updated Apr 11, 2025Results posted

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

A Phase 1 interventional study of BIA 2-093 and Moxifloxacin in Epilepsy, sponsored by Bial - Portela C S.A.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Bial - Portela C S.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing eslicarbazepine in Epilepsy — none open to participants now, none under way, none of them phase 3. eslicarbazepine · Epilepsy.

Enrollment
14th of 45
67 · median 32
Started
2007
with 6 others
Phase 1
29 of 45
none open now
Registered
32nd of 45
by date
Lead sponsor
40 of 45
Bial - Portela C S.A.

Among the 45 studies testing eslicarbazepine in Epilepsy, this one is the 14th largest by enrollment, is one of 7 that started in 2007, is one of 29 in phase 1, and was the 32nd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 45 studies testing eslicarbazepine in Epilepsy is open now. The open studies under Epilepsy, anywhere →

About eslicarbazepine

eslicarbazepine: first FDA approval 2013 (APTIOM), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing eslicarbazepine in Epilepsy as a file.
02

Study summary

A randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover trial to evaluate the effect of eslicarbazepine acetate on cardiac repolarization in healthy adult men and women

Read the detailed description

The purpose of this randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover study was to evaluate the effect of therapeutic and supra-therapeutic doses of eslicarbazepine acetate on the placebo corrected time-matched change from baseline using individually corrected QT (QTcI) interval durations in adult healthy volunteers.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be a healthy male or female 18 to 45 years of age. Women were required to be (more than 12 months since last period); surgically sterile (hysterectomy or tubal ligation at least 6 months prior to enrollment); using an intrauterine device; or double barrier (i.e. diaphragm or spermicide plus male condom) non-hormonal therapy for the duration of the trial and were required to have a negative pregnancy test at screening and upon each check-in to the study facility.
  • Have a within the range of 18-30 kg/m2.
  • Be able to communicate effectively with the study personnel.
  • Have no significant disease or abnormal laboratory values as determined by medical history, physical examination or laboratory evaluations, conducted at the screening visit and on each admission to the clinic.
  • Have a normal 12-lead , without any abnormalities of rate, rhythm or conduction.
  • Be nonsmokers defined as not having smoked in the past 6 months.
  • Be adequately informed of the nature and risks of the study and give written prior to study entry.

Exclusion criteria

Exclusion Criteria:

  • Known or allergy to moxifloxacin, eslicarbazepine acetate or related compounds such as carbamazepine, oxcarbazepine, or licarbazepine.
  • Women who were pregnant or breast feeding.
  • Any disease or condition (medical or surgical) which, in the opinion of the investigator, might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or placed the subject at increased risk.
  • A sustained supine systolic blood pressure > 140 mmHg or \<100mm Hg or a diastolic blood pressure > 95 mmHg at screening or baseline.
  • A resting heart rate of \<50 bpm or >100 bpm.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Treatment Sequence ABCD

    A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days

    Drug: BIA 2-093 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Treatment Sequence BDAC

    A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days

    Drug: BIA 2-093 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Treatment Sequence CADB

    A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days

    Drug: BIA 2-093 · Drug: Moxifloxacin · Drug: Placebo

  • Experimental
    Treatment Sequence DCBA

    A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days

    Drug: BIA 2-093 · Drug: Moxifloxacin · Drug: Placebo

Interventions

  • Also known as: ESL, Eslicarbazepine acetate

  • Also known as: avalox

  • DrugPlacebo

    Also known as: PLC

06

What researchers measure

Primary outcomes

  1. QTcI - QT Interval Individually Corrected for Heart Rate - Day 5

    Time frame: -30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose

Secondary outcomes

  1. QTcB - QT Interval Corrected for Heart Rate Using Bazett's Formula

    Time frame: -30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose

  2. QTcF - QT Interval Corrected Using Fridericia's Formula

    Time frame: -30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose

07

Results

Posted Dec 22, 2014

Participant flow

Participant flow — Overall Study
MilestoneTreatment Sequence ABCDTreatment Sequence BDACTreatment Sequence CADBTreatment Sequence DCBA
Started17171716
Completed16131214
Not completed1452
Withdrew: Adverse event1351
Withdrew: Withdrawal by subject0101

Outcome measures

PrimaryQTcI - QT Interval Individually Corrected for Heart Rate - Day 5
Time frame:
-30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose
Reported as:
Mean · msec
QTcI - QT Interval Individually Corrected for Heart Rate - Day 5
msecBIA 2-093 1200 mgBIA 2-093 2400 mgMoxifloxacin 400 mgPlacebo
0.5 hr-8.05 ± 12.168-6.15 ± 10.891-2.77 ± 10.496-4.39 ± 9.985
1 hour-9.34 ± 11.399-7.34 ± 11.8223.80 ± 11.824-4.14 ± 9.515
1.5 hours-8.70 ± 11.689-8.67 ± 10.5255.30 ± 11.537-4.22 ± 10.432
2 hours-9.48 ± 10.692-8.31 ± 10.7386.87 ± 11.477-5.32 ± 10.189
3 hours-8.04 ± 11.188-8.50 ± 13.1428.49 ± 12.875-3.24 ± 11.178
4 hours-7.72 ± 12.496-6.16 ± 13.56310.13 ± 11.686-2.10 ± 9.899
5 hours-3.54 ± 11.282-1.71 ± 12.5677.07 ± 11.309-0.75 ± 10.090
6 hours-4.59 ± 11.792-2.64 ± 12.8565.83 ± 10.927-3.10 ± 10.537
8 hours-2.63 ± 10.841-1.36 ± 11.2815.80 ± 12.303-1.77 ± 10.586
12 hours-0.01 ± 9.3470.03 ± 13.3115.85 ± 9.955-1.44 ± 9.150
16 hours-3.72 ± 10.863-4.65 ± 12.9305.21 ± 10.900-1.41 ± 12.835
23.5 hours-3.36 ± 11.514-0.06 ± 12.6052.39 ± 9.104-1.71 ± 9.513
SecondaryQTcB - QT Interval Corrected for Heart Rate Using Bazett's Formula
Time frame:
-30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose

Results for this outcome have not been posted.

SecondaryQTcF - QT Interval Corrected Using Fridericia's Formula
Time frame:
-30 minutes (pre-dose) 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 23.5 hours post-dose

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Sequence ABCD—0/17 (0%)1/17 (5.9%)
Treatment Sequence BDAC—0/17 (0%)3/17 (17.6%)
Treatment Sequence CADB—0/17 (0%)5/17 (29.4%)
Treatment Sequence DCBA—0/16 (0%)1/16 (6.3%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventTreatment Sequence ABCDTreatment Sequence BDACTreatment Sequence CADBTreatment Sequence DCBA
dizzinessNervous system disorders1/173/175/171/16
HEADACHENervous system disorders1/173/175/170/16
Paraesthesia oralNervous system disorders0/173/173/171/16
SomnolenceNervous system disorders0/172/173/171/16
vomitingGastrointestinal disorders1/172/172/170/16
NauseaGastrointestinal disorders0/171/172/170/16
RashSkin and subcutaneous tissue disorders1/171/170/171/16
PruritusSkin and subcutaneous tissue disorders0/170/171/171/16
VISION BLURREDEye disorders0/170/171/171/16
abdominal distensionGastrointestinal disorders0/170/171/170/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment Sequence ABCDTreatment Sequence BDACTreatment Sequence CADBTreatment Sequence DCBATotal
Mean36.2 ± 7.5533.6 ± 6.4132.6 ± 7.8835.8 ± 7.3534.5 ± 7.31
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence ABCDTreatment Sequence BDACTreatment Sequence CADBTreatment Sequence DCBATotal
Female7910935
Male1087732
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence ABCDTreatment Sequence BDACTreatment Sequence CADBTreatment Sequence DCBATotal
American Indian or Alaska Native01001
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American40419
White1316131557
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Comprehensive Phase OneTM
    Miramar, Florida 33025, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 7 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2014
First posted
Nov 5, 2014
Start
Mar 2007
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Results first posted
Dec 22, 2014
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02283788
Responsible party
Sponsor
First posted
Nov 5, 2014
Start date
Mar 2007
Primary completion
Jun 2007
Completion
Jun 2007
Results posted
Dec 22, 2014
Last update
Apr 11, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eslicarbazepine

Start the discussion